Ceres Pharma acquires Italian Amnol group.
Ceres Pharma NV, a Belgian based pharmaceutical company, active in Women and Family Healthcare, has acquired the Italian pharmaceutical group Amnol S.r.l.
The entry of Ceres Pharma in Italy is an important step in the execution of Ceres Pharma’s strategy to build an important position in Women and Family Healthcare in Europe.
Amnol is a leading Italian pharmaceutical group specialized in the phlebology and lymphology therapeutic areas in Italy. In the phlebology therapeutic area, Wasotonal®, Flebonorm® and Venovigor® are strong and trusted brands among Italian doctors, pharmacists and patients. In the lymphology therapeutic area, Cumadren®, Linfonorm® and Linfoguard® are the key brands. Amnol promotes its brands through doctors via a large and reliable network of Scientific Informants covering the entire Italian market and specialists doctors. Next to Amnol, Ceres Pharma acquired also Euronational. Euronational, 100% owned by Amnol, is a smaller pharmaceutical company specialized in food supplements and dermo cosmetics for the maintenance of body functions in various therapeutic areas. In 2022 the Amnol group realized a turnover of more than 7 million euros.
"I am very happy that we have come to an agreement with the Amnol group. This acquisition fits perfectly within Ceres Pharma’s strategy. Meanwhile, Ceres Pharma has developed an important position in Belgium and in Central and Eastern Europe and we are looking to also build a position in Southern Europe (Italy & Spain). The Amnol group is our first step to enter Italy. Amnol has strong brands in phlebology and lymphology and these therapeutic areas fit very well in our Women and Family Health strategy”, says Mario Debel, CEO of Ceres Pharma.
All Amnol group’s employees, including the shareholders Antonella Della Piana, Carlo Della Piana and Giorgio Stefanelli, shareholder and CEO, remain on board. “We are pleased to be part of a strong, dynamic and fast growing international group, such as Ceres Pharma. Together, we will be stronger to execute our ambitious growth plan in Italy and we will be able to sell our products in Belgium and other Central and Eastern European countries", says Giorgio Stefanelli, CEO of Amnol group.
The price of the takeover will not be disclosed.
For more information, please contact:
Mario Debel, CEO Ceres Pharma: +32 479 65 67 43
www.ceres-pharma.com www.amnol.net www.euronational.it
Amnol is a leading Italian pharmaceutical group active in the development and distribution of qualitative and innovative food supplements and dermo cosmetics, mainly in the phlebology and lymphology therapeutic areas in Italy.
About Ceres Pharma
Ceres Pharma is a dynamic and fast growing, Belgian based, pharmaceutical company, founded in 2017 by Mario Debel and Alychlo and acquired in 2021 by Naxicap Partners. It is the ambition of Naxicap and the founder and CEO Mario Debel to grow Ceres Pharma through the development of its own product portfolio as well as through acquisitions. Ceres Pharma is active in the development and distribution of drugs, medical devices, biocides, cosmetics, qualitative food supplements and pharmaceutical preparations in the Benelux and in Central and Eastern Europe and now also in Italy.
About Naxicap Partners
As one of the top private equity firms in France, Naxicap Partners - an affiliate of Natixis Investment Managers - has €5 billion in assets under management. As a committed, responsible investor, Naxicap Partners builds solid, constructive partnerships with entrepreneurs so that their projects can succeed. The firm has 39 investment professionals spread across five offices in Paris, Lyon, Toulouse, Nantes and Frankfurt.